Job Title: President and Chief Officer
Dr. Douville is the new President and Chief Executive Officer of IRICoR, a pan-Canadian leader in the de-risking of early-stage academic assets in the field of drug discovery. IRICoR’s mandate is to accelerate the discovery, development, and commercialization of novel highly innovative therapies in cancer and rare diseases by establishing strategic partnerships with industry or creating spinoff companies.
Prior to this role, she was the Founder and Managing Partner of AmorChem, a leading early-stage venture capital fund focusing on academic innovation and translating it into early-stage biotech companies. As a venture capitalist with more than 25 years of life sciences’ investment experience, she has raised and managed funds, and has sourced, led and overseen several investments in biotech companies, in promising university technologies, and successfully created several spin-off companies that have raised capital or partnered with pharmaceutical companies. She is an active participant in the life sciences’ ecosystem and several not-for-profit organisations. She is the Chair of Genome Canada, a Member of the Canada Foundation for Innovation and a member of the Policy Engagement Committee of Research Canada. She is also currently an active board member of Corbin Therapeutics Inc. and SemaThera Inc.
Dr. Douville trained as a biochemist, obtaining her PhD in Biochemistry from the University of Ottawa and a post-doctoral fellowship from the Imperial Cancer Research Fund in London, UK. She also has a Certificate in Management from CIREM/HEC and a Certificate in Leadership and Leadership Abilities from the Leadership Institute. More recently, she received the ICD.D designation from the Institute of Corporate Directors.